PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-2.60%
Both companies show declining cash positions (-2.60% vs TRAW's -9.05%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-2.60%
Below half of TRAW's -9.05%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.51%
Other current assets growth < half of TRAW's -86.80%. David Dodd sees a leaner approach to short-term items.
-2.19%
Below half of TRAW's -10.07%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-4.69%
Below half TRAW's -14.29%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.67%
Higher Long-Term Investments Growth compared to TRAW's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.21%
Below half of TRAW's -13.80%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-2.25%
Below half of TRAW's -10.07%. Michael Burry sees a potential red flag for stagnation or capital shortage.
28.73%
Above 1.5x TRAW's 2.66%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
27.69%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
38361.54%
Higher Deferred Revenue (Current) Growth compared to TRAW's zero value, indicating better performance.
-27.69%
Less than half of TRAW's 174.83%. David Dodd sees fewer expansions in other current obligations.
27.28%
Above 1.5x TRAW's 9.68%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.34%
Less than half of TRAW's -1.82%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
4.72%
Similar yoy to TRAW's 6.28%. Walter Schloss sees parallel expansions in total liabilities.
4.00%
Higher Common Stock (Book Value) Growth compared to TRAW's zero value, indicating worse performance.
-3.83%
≥ 1.5x TRAW's -1.18%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.70%
Below half TRAW's -15.17%. Michael Burry sees potential underperformance in building shareholder capital.
-2.25%
Below half TRAW's -10.07%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.67%
Higher Total Investments Growth compared to TRAW's zero value, indicating better performance.
-0.77%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
2.64%
Less than half of TRAW's 9.05%. David Dodd sees better deleveraging or stronger cash buildup than competitor.